How The Story On Advanced Enzyme Technologies (NSEI:ADVENZYMES) Is Evolving Around A ₹370 Fair Value

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

The fair value estimate for Advanced Enzyme Technologies is held at ₹370, with analysts choosing not to shift their valuation anchor despite refreshed model inputs. That steady price target lines up with commentary that the key question now is execution against the current plan rather than a change in the core story. As you read on, you will see how this stable ₹370 figure fits into the evolving analyst narrative and what it means for your own view on the stock.

Stay updated as the Fair Value for Advanced Enzyme Technologies shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Advanced Enzyme Technologies.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

Recent research on Advantage Solutions from Morgan Stanley highlights how refreshed models can lead to higher valuation anchors when analysts gain confidence in their assumptions, which is relevant as you think about how Advanced Enzyme Technologies might be assessed against its own ₹370 fair value marker. Canaccord’s repeated coverage of Advantage Solutions, including model updates after quarterly results, shows that consistent analyst engagement can support a clearer story around cash flow quality and business focus. This framework is one investors can also apply when reviewing Advanced Enzyme Technologies.

🐻 Bearish Takeaways

The fact that Canaccord previously reduced its price target on Advantage Solutions after revisiting cash flow and portfolio details is a reminder that valuation anchors can shift when execution or financial quality falls short. This is a risk investors should keep in mind for any stock trading near a fair value estimate. Target revisions in the Advantage Solutions coverage also underline that analysts usually wait for more evidence from reported numbers before moving valuation meaningfully. This can limit upside if Advanced Enzyme Technologies underdelivers against current expectations embedded in the ₹370 figure.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!NSEI:ADVENZYMES 1-Year Stock Price Chart

See how Advanced Enzyme Technologies' fair value stacks up across multiple valuation models — not just analyst targets.

What's in the News

Advanced Enzyme Technologies has scheduled a board meeting on May 09, 2026 to consider and approve the standalone and consolidated annual financial statements for the year ended March 31, 2026, along with the fourth quarter results. At the same meeting, the board plans to consider and recommend a final dividend, if any, for the financial year ended March 31, 2026. The board will also consider and declare an interim dividend, if any, for the financial year ending March 31, 2027, indicating that payout decisions for the new year are already on the agenda.

Story Continues

How This Changes the Fair Value For Advanced Enzyme Technologies

Fair value estimate is unchanged at ₹370.0. Revenue growth assumption is adjusted to 12.79% from 16.14%. Net profit margin assumption is 20.17% compared with 20.23% previously. Future P/E multiple is set at 26.04x versus 26.31x earlier. Discount rate is refined to 12.72% from 12.95%.

Never Miss an Update: Follow The Narrative

Narratives link a company's real world story to a financial forecast and fair value, so you can see how business developments feed into the long term numbers. They refresh as new data and commentary come through, keeping the investment case current.

Head over to the Simply Wall St Community and follow the Narrative on Advanced Enzyme Technologies to stay up to date on:

How expansion into health, wellness, and B2C nutrition products connects to the role of enzymes and probiotics in preventive care. Progress in biocatalysis and other sustainable enzymatic solutions, plus the impact of new R&D centers and international subsidiaries on product breadth. Key risks such as tariff related margin pressure, slower than expected scaling of new segments, and reliance on a relatively narrow product and customer base.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ADVENZYMES.nsei.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments